The Liberty system is designed to improve the endovascular procedures. Credit: Terelyuk / Shutterstock.

Microbot Medical and Emory University in the US have signed an agreement to assess the future autonomous capabilities of the Liberty endovascular robotic surgical system.

Under the agreement, the university will be responsible for exploring the feasibility of integrating the surgical system with an imaging system for creating an autonomous robotic system to carry out endovascular procedures.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The evaluation will be led by Amir Pourmorteza from Emory University Department of Radiology and Imaging Sciences at the Winship Cancer Institute, and the Department of Biomedical Engineering at Georgia Institute of Technology, under Project Trita.

Pourmorteza said: “Autonomous robotics has the potential to standardise outcomes, improve efficiencies, reduce radiation exposure, and democratise access to top-level healthcare.

“Project Trita merges CT guidance, artificial intelligence, and medical robotics.”

The Liberty system is designed to improve endovascular procedures by eliminating the need for large equipment while reducing radiation exposure.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Microbot Medical CEO, president and chairman Harel Gadot said: “Our vision for the future of endovascular robotics includes autonomous capabilities, which have the potential to standardise endovascular procedures and improve access to benefit millions of patients globally.

“We believe Liberty can be integrated with imaging, planning and navigation software to ultimately create an autonomous robotic system that can be used in endovascular procedures.”

In June 2024, Microbot Medical secured the US Food and Drug Administration approval to proceed with its pivotal human clinical trial for its Liberty system.

The Brigham and Women’s Hospital in Boston, Massachusetts will serve as one of the clinical trial sites to perform the pivotal human study of the Liberty system.